论文部分内容阅读
目的 研究细胞增殖状态与肺癌临床病理生理特征和预后的关系 ,探讨 Ki6 7对临床诊断和预后判断的价值。 方法 应用免疫组织化学法检测 16 6例肺癌组织标本和 37例肺良性病变组织中 Ki6 7的表达水平。 结果 (1)肺癌组织中 Ki6 7指数显著高于肺良性病变组织 (P<0 .0 1) ,而癌旁组织与良性病变组织相比差别无显著性意义 ;(2 )肺癌组织中 Ki6 7表达水平增强与肺癌组织学类型、细胞分化程度有关 (P<0 .0 5 ) ,而与患者 PTNM分期、淋巴结转移程度、吸烟与否以及患者的性别、年龄无明显关系 ;(3) Ki6 7高表达组肺癌患者的术后生存时间显著低于低表达组 (P<0 .0 1) ,按 PTNM分期分层后这种差别仍然存在 (P<0 .0 5 )。 结论 Ki6 7能较好地反映肺癌细胞的增殖状态 ,并对临床诊断和预后判断有一定价值
Objective To study the relationship between cell proliferation status and clinical pathophysiological characteristics and prognosis of lung cancer, and to explore the value of Ki67 in clinical diagnosis and prognosis. Methods Immunohistochemistry was used to detect Ki6 7 expression levels in 16 6 lung cancer specimens and 37 lung benign lesions. Results (1) Ki67 index in lung cancer tissue was significantly higher than that in benign lung lesions (P < 0.01). There was no significant difference between paracancerous tissue and benign lesions. (2) Ki67 in lung cancer tissues. The enhancement of expression level was related to the histological type and differentiation of lung cancer (P<0.05), but it was not significantly related to PTNM stage, lymph node metastasis, smoking or not, gender and age of patients; (3) Ki6 7 The survival time of patients with high expression of lung cancer was significantly lower than that of patients with low expression (P<0.01), and this difference was still present after stratification by PTNM (P<0.05). Conclusion Ki67 can well reflect the proliferation status of lung cancer cells, and it has a certain value for clinical diagnosis and prognosis judgment.